Details of Drug-Drug Interaction
| Drug General Information (ID: DDIA945MZ7) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Cimetidine | Drug Info | Doxepin (topical) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiulcer Agents | Antidepressants | |||||||
| Structure | |||||||||
| Mechanism of Cimetidine-Doxepin (topical) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Decreased metabolism (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Cimetidine | Doxepin (topical) | |||||||
| Mechanism | Inhibit the hepatic metabolism of doxepin | Doxepin | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetics | ||||||||
| Factor Description | Alters the metabolism of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients should be advised to notify their physician if they experience increased sedation, blurry vision, severe dry mouth, or urinary retention. Ranitidine has not been found to affect serum concentrations of tricyclic antidepressants and may be a better alternative. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Zonalon (doxepin topical). Bioglan Pharmaceutical Inc, Malvern, PA. | ||||||||||||||||||